ABBV slides around 2.5% as technical indicators warn of overbought conditions despite bullish momentum

Traders Union
All News
Stocks
AbbVie slides 2.53% today amid volatility

Highlights

AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics and received new FDA approval for an undisclosed product.
Second-quarter 2026 revenue came in at $16.99 billion, up 10.2% year-over-year, with third-quarter earnings guidance set at $3.84 to $3.88 per share.
AbbVie stock remains above key moving averages amid overbought conditions, with a 5-day expected range of $266.23 to $281.79.

Ongoing selloff persists as milestone achievements fail to lift shares

AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026. During the same period, AbbVie received new FDA approval for an undisclosed product and presented 22 research abstracts on inflammatory bowel disease, including positive late-stage data for RINVOQ. The company also reported second-quarter 2026 revenue of $16.99 billion, a 10.2% increase year-over-year, and issued third-quarter earnings guidance of $3.84–3.88 per share. Positive Phase 3 trial results for Epkinly in collaboration with Genmab were also reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees AbbVie's recent 2.53% pullback as an early warning after strong news catalysts and significant overbought technicals. He notes that the sharp rise in RSI and extreme readings on CCI and Stochastic RSI often foreshadow corrections, especially when price reverses after a gap up. Momentum may look positive, but buying interest is stretched, while profit-taking suggests skepticism about sustained upside. Improved fundamentals from acquisitions and earnings could attract investors, yet valuations may be ahead of themselves given volatility. "Traders should exercise caution as technical overextension and broad selling pressure signal increased downside risk despite bullish headlines," he warns.

Viktoras Karapetjanc, expert at Traders Union, views AbbVie's fundamental outlook as robust following strategic acquisitions, positive FDA decisions, and double-digit revenue growth. He emphasizes that the bullish structure remains intact, supported by strong guidance and new product momentum. The recent pullback is seen as normal profit-taking within a healthy uptrend, not as a shift in sentiment. He believes investors have multiple opportunities amid promising late-stage trial results and enhanced long-term prospects. "AbbVie continues to offer further growth potential, and I see the recent volatility as a constructive reset for new upside moves," he states.

Parshwa Turakhiya, analyst, observes that sentiment is conflicting — technicals show strong momentum, but overbought signals are flashing yellow. He finds the $266.23-$281.79 volatility band compelling for short-term traders seeking quick moves. The initial breakout attempt was negated by swift profit-taking, reflecting choppy participation. Turakhiya notes that intraday reversals reward nimble strategies. "Look for fast setups inside the range, but manage risk tightly as sentiment can flip in either direction on a headline," he advises.

Overbought conditions emerge as bullish momentum meets resistance

AbbVie is trading above its 20-day, 50-day, and 200-day moving averages at $266.24, $259.48, and $232.91, indicating bullish momentum across all timeframes. The immediate ceiling remains at $280.15 and key support is at $266.24, with the Ichimoku Kijun at $264.06 providing further evidence of upside bias. Momentum indicators remain sharply positive: MACD and ADX both signal buying interest. However, the RSI is elevated at 74.1 and both the Stochastic RSI and Commodity Channel Index (CCI) register extreme overbought readings, suggesting caution for fresh longs. Bull/Bear Power at 11.6 highlights strong intraday buying, but is also overbought. The Awesome Oscillator confirms continued buying strength. After opening with a $2.17 upside gap, the stock reversed to near the session’s low, with 1.13% intraday volatility indicating notable profit-taking after a strong start, despite still-bullish technical momentum.

Earlier, analysts noted that AbbVie's ongoing clinical progress and strong technical momentum warranted a constructive but cautious outlook due to persistent overbought signals. The current price action, characterized by elevated technical indicators and profit-taking despite robust fundamentals, introduces a higher risk of volatility around the $266.23–$281.79 range, making these levels key for near-term trading decisions.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.